周四,新西兰基准标准普尔/NZX 50指数上涨2.2%,收于12492点,结束了连续四天的下跌,创下自5月31日以来的最大单日涨幅。医疗科技股领涨市场反弹,权重股斐雪派克和埃伯斯集团分别上涨4.45%和2.3%。此外,Pacific Edge的股价飙升11.85%,该公司正在等待美国对其Cxbrader测试的医疗保险覆盖状态的决定。此外,养老院运营商Ryman、Arvida和Oceania分别增长了4.7%、0.6%和1.3%。大盘股公用事业股也大幅上涨,Meridian上涨1%,Infratil上涨3.6%,Contact上涨3.8%。与此同时,投资者现在正在等待美联储主要官员在当天晚些时候的演讲,以了解美联储降息步伐的线索。
New Zealand's benchmark S&P/NZX 50 index jumped 2.2% to close at 12,492 on Thursday, ending a four-day losing streak with its largest one-day gain since May 31. The market rebound was led by health technology stocks, with heavyweights Fisher & Paykel and Ebos Group rising 4.45% and 2.3%, respectively. Additionally, shares of Pacific Edge surged 11.85% as the company awaited a US decision on the Medicare coverage status for its Cxbladder tests. Moreover, retirement-home operators Ryman, Arvida, and Oceania added 4.7%, 0.6%, and 1.3%, respectively. Large-cap utility stocks also recorded significant increases, with Meridian up 1%, Infratil climbing 3.6%, and Contact rising 3.8%. Meanwhile, investors are now awaiting speeches from key Federal Reserve officials later in the day for clues on the pace of the US central bank's interest rate cuts.